---

$14.86

-0.0900 ( -0.87% ) 49.1K

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-01-15	Buy	74125.00	EcoR1 Capital, LLC
2025-01-10	Buy	21021.00	EcoR1 Capital, LLC
2024-04-02	Sale	-74000.00	Gallagher Neil
2024-02-09	Sale	-74000.00	Cesano Alessandra
2024-01-08	Sale	-47666.00	Galbraith Kenneth
2024-01-08	Sale	-90000.00	Smith Jeffrey T L
2024-01-08	Sale	-10500.00	Astle Christopher
2024-01-08	Sale	-17166.00	Moore Paul Andrew
2023-12-28	Buy	5086521.00	EcoR1 Capital, LLC
2023-12-11	Sale	-1550.00	Astle Christopher

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.